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Abstract  
Background–Trastuzumab has conferred significant clinical benefits in HER-2-positive breast 
carcinomas. HER-2 status is determined by immunohistochemistry (IHC) and/or fluorescence in situ 
hybridization (FISH), but appropriate assessment of HER2 status remains subject to considerable 
debate. Data on the health economic impact of HER2 test strategies are limited. 
Methods–A life-long Markov state transition model was used to assess costs and effectiveness of 
HER2 assay strategies (based on IHC, FISH, both combined or FISH confirmation of IHC2+) for a 
hypothetical cohort of early breast cancer patients from the perspective of the Swiss health system. 
We compared clinically relevant strategies of predictive testing and subsequent trastuzumab treatment 
of HER-2-positive patients only.  
Results– FISH testing was the most cost-effective strategy with an incremental cost-effectiveness 
ratio of €12’245 per additional quality adjusted life year (QALY) gained, compared to no trastuzumab 
treatment. The next best strategy was parallel IHC and FISH, with costs of €400’154/QALY gained 
compared to FISH alone. FISH as primary HER-2 testing modality remained the preferred option in 
deterministic and probabilistic sensitivity analysis.  
Conclusion– Predictive testing to identify adjuvant breast cancer patients who benefit from 
trastuzumab treatment is a clinical and economic necessity. Our model identifies FISH as the most 
cost-effective approach.  
 
Keywords: cost-effectiveness, adjuvant, breast cancer, predictive tests, trastuzumab 
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Introduction  
Human epidermal growth factor receptor 2 (HER-2/neu, hereafter referred to as HER-2), is a 
transmembrane receptor tyrosine kinase expressed in epithelial cells including the breast. 
Approximately 20-25 percent of breast cancers patients show HER-2 protein overexpression and/or 
HER-2 oncogene amplification,[1-4]. Both are markers for aggressive disease[5, 6] and the molecular 
targets of trastuzumab (Herceptin®, Roche Pharma, Switzerland) and lapatinib (GlaxoSmithKline, 
London, United Kingdom). Trastuzumab, a humanized monoclonal antibody, is used successfully in 
the therapy of HER-2-positive invasive breast carcinomas[7-10]. In the adjuvant setting, it substantially 
reduces recurrence rates and overall mortality in combination with chemotherapy[11-14]. There is now 
consensus on a life-prolonging effect in metastatic, early node-positive and node-negative HER-2 
positive invasive breast cancers. Trastuzumab has also dramatically increased treatment costs[15]. 
Gene amplification and protein overexpression can be identified by immunohistochemistry (IHC) or 
fluorescence in situ hybridisation (FISH), respectively[7]. Despite a long history of predictive HER-2 
testing in breast cancer patients, there is still no consensus on the most appropriate testing approach. 
Selection criteria include accuracy, reproducibility and precision but also cost[16]. Published results 
comparing HER-2 status determined by FISH or IHC in formalin fixed, paraffin embedded (FFPE) 
tissues are contradictory. Standardization of IHC in FFPE tissue samples is difficult due to pre-
analytical problems and high subjectivity in interpretation. Concordance rates range between 80% and 
90%, depending on the methodology, instrumentation and experience of the laboratories carrying out 
the tests[17]. This implies significant numbers of false negative test results, which may have dramatic 
consequences for the affected patients[18]. Current American Society of Clinical Oncology and the 
College of American Pathologists (ASCO-CAP) guidelines recommend the use of IHC for initial 
evaluation of HER-2 status but initial use of FISH is also discussed[19]. Arguments for FISH include 
better reproducibility and accuracy, although FISH is more expensive than IHC[20]. 
Expensive new cancer therapies are usually regarded as appropriate if trial data show clinically 
relevant improvements[21, 22]. Several publications have addressed the cost-effectiveness of 
trastuzumab in HER-2-positive breast cancer patients[23-25]. Markov models have been used to 
evaluate the cost-effectiveness of HER-2 testing strategies in the adjuvant and metastatic settings[26-
28] but comprehensive cost-effectiveness analysis comparing alternative assay strategies are limited.  
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Using a life-long Markov state transition model, we evaluated the health economic impact of 
trastuzumab treatment of adjuvant breast cancer in Switzerland and the influence of different HER-2-
testing strategies (IHC, FISH, both combined, or FISH confirmation of IHC 2+ status)[29]. The model 
can also be used for similar decision problems arising with other predictive tests in pathology. 
Methodology 
Overview of breast cancer disease model 
A Markov model with a cycle length of 1 year was used to reproduce the disease process and 
economic consequences. Economic endpoints were the costs associated with each strategy. 
Effectiveness was assessed as quality-adjusted life-years (QALYs). Incremental cost-effectiveness 
ratios (ICERs) were planned to be calculated if applicable, i.e. in non-dominant situations. The time 
horizon of the analysis was life-long (50 years). 
Costs were assessed from the perspective of the Swiss health care system. Consequently, non-
medical and indirect costs were disregarded. Direct medical costs included drug costs, costs for 
predictive testing (where applicable), gynaecological examinations, diagnostic procedures and 
hospitalization (Table 3). Costs and effects were discounted at 3%[21]. Costs are shown in Euros (€). 
In March 2009, €1.00 equalled Swiss Francs (CHF) 1.50. 
Patient populations studied 
The model assessed a hypothetical cohort of female breast cancer patients aged 50 years, of whom 
20% were HER-2-positive. The HER-2-positive patient population was defined by the eligibility criteria 
of the HERA trial[12]. In brief, patients had centrally validated HER-2-positive early stage invasive 
breast cancer with either node-positive or node-negative disease status (disease free status). They 
completed local regional therapy and at least four courses of predefined standard adjuvant or 
neoadjuvant chemotherapy. Eligibility criteria for disease free HER-2-negative patients were WHO 
performance status 0-1 with a confirmed HER-2-negative status. They had undergone breast surgery 
with axillary-node dissection or sentinel-node biopsy for invasive breast carcinoma[11]. 
Strategies compared 
We assessed the following testing strategies: IHC alone, FISH alone, parallel IHC and FISH, 
sequential testing with FISH confirmation of IHC 2+. Patients with positive IHC (2+ or 3+) and/or 
positive FISH received adjuvant trastuzumab treatment. Patients with no or a very low HER-2 
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expression levels (IHC 0 or 1+ or negative FISH) received standard treatment. Costs and effects of no 
trastuzumab treatment and a strategy of trastuzumab treatment of all patients with no predictive 
testing were used as reference values. The latter does not represent a clinically relevant option but 
was added to demonstrate the overall magnitude of the benefits achieved with predictive testing.  
False positive and false negative test results lead to inadequate treatment of the affected patients. 
Sensitivity and specificity of IHC and FISH was assessed from published literature[30]. Sensitivity and 
specificity of the parallel testing strategy were calculated according to the “believe-the-positive” 
approach, i.e. the combined result was positive if one test indicated a positive result. Both tests were 
regarded as conditional independent (Table 1)[31]. 
Disease stages 
The simulated population moved through distinct disease states, namely disease free survival, local 
recurrence, regional recurrence, metastatic disease and death (Figure 1). Local recurrence was 
defined according to the American Joint Committee on Cancer (AJCC) as isolated ipsilateral in-breast 
cancer recurrence after breast-conserving therapy of a stage 0-III breast carcinoma[32]. Regional 
recurrence included patients with cancer recurrence in the axilla with or without in-breast recurrence 
after breast-conserving therapy of  stage 0-II breast carcinoma[33]. Metastatic disease implied women 
with progressive metastatic breast cancer without previous chemotherapy treatment for metastatic 
disease[7]. 
Clinical data sources 
Clinical model inputs, namely state transition probabilities for patients with HER-2-positive and HER-2-
negative breast carcinomas (Table 2), were derived from the literature. We disregarded phase II trials, 
studies only presented as conference abstracts, studies with very low sample size, and studies with 
insufficient information for being used in our model. Efficacy results from studies of monoclonal 
antibodies targeted against HER-2 other than trastuzumab were not taken into account. Modelling of 
disease free survival was based on HERA[12]. We assumed that HER-2-positive individuals with 
trastuzumab treatment would have the same transition probabilities as the patients receiving adjuvant 
trastuzumab in HERA. The recurrence rates seen in the HERA comparator group were applied to our 
HER-2-positive group without trastuzumab treatment. In the HER-2-negative situation, transition 
probabilities were assumed to be unaffected by trastuzumab treatment[11].  
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The future history of patients entering the local and regional recurrence states was derived from 
published retrospective reviews of medical records and was not dependent on HER-2 status[34, 35]. 
One-year survival rates in metastatic breast cancer patients stemmed from two phase III trials of 
standard treatment plus trastuzumab versus best supportive care[7, 36]. It was assumed that after 5 
years, the risk of reappearing metastasis would decline by 10% annually[37].  
Overall mortality rates of the Swiss female population was taken from published Swiss life tables[38].  
Utilities 
Utilities were based on a study using the self-administered EQ-5D questionnaire[39]. Responses were 
combined with visual analogue scale-based population preference values. Utilities per disease stage 
were: first year after primary breast cancer, 0.696 (95% confidence interval (CI) 0.634-0.725); first year 
after recurrence, 0.779 (CI 0.700-0.849); second and subsequent years after primary breast 
cancer/recurrence, 0.779 (CI 0.745-0.811); metastatic disease state, 0.685 (CI 0.620-0.735)[39]. 
Medical resource use  
HER-2-positive group 
Disease free status 
HER-2-positive patients received trastuzumab after excision of early-stage breast cancer and 
completion of chemotherapy. Trastuzumab dosing and planned treatment duration corresponded to 
the regimen used in HERA, with a 8 mg/kg loading dose and 6 mg/kg dose every 3 weeks during one 
year[12]. We assumed that 15% of the patients would receive an additional 150 mg vial due to higher 
weight (>74 kg). Echocardiography was performed quarterly during trastuzumab treatment[12]. All 
patients received gynaecological examinations[40]. During five years, half of HER-2-positive patients 
were treated with aromatase inhibitors (letrozol 2.5 mg/day or anastrozol 1 mg/day)[12].  
Local and regional recurrence 
Mammography, gynaecological examinations, diagnostic ultrasound, radiotherapy and surgery 
including hospitalization, and aromatase inhibitors (as described above) were used in these 
patients[25]. Local recurrence was assumed to be localized in the thoracic wall (40%) or in the breast 
(60%)[41]. 
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Metastatic state 
Chemotherapy, radiotherapy, diagnostic ultrasound and palliative surgery including hospitalization, 
and aromatase inhibitors (as described above) were used in these patients[25]. We assumed that 80% 
of the patients responded to trastuzumab treatment in the first-line therapy and that half of these 
patients were re-treated with trastuzumab for an additional year when metastases were diagnosed[7].  
Untested group 
Untested patients all received trastuzumab treatment as described for the HER-2-positive group. 
Aromatase inhibitor was given to 70% of these patients for five years[12, 42, 43]. 
HER-2-negative group 
Patients with no HER-2 overexpression did not receive trastuzumab but were otherwise treated as 
described for the HER-2-positive group. During five years, 70% were assumed to receive hormone 
therapy[42, 43]. 
Unit costs 
Unit costs (Table 3) for laboratory and diagnostic interventions were derived from the official Swiss 
tariff list[44]. Hospital case-based flat rates and day rates were based on Swiss Diagnosis Related 
Groups (DRGs)[45]. Length of hospital stay was based on data provided by the Swiss Federal Statistic 
Office[46]. Drug costs based on official Swiss pharmacy prices[47]. Costs of diagnostics and 
therapeutic interventions in each state were assessed on this basis. However, as the adjuvant therapy 
was assumed to be the same for all patients, costs of initial treatment (primary breast surgery and 
adjuvant chemotherapy) were not included. 
Sensitivity analysis 
Deterministic sensitivity analysis tested the precision and robustness of the results. Parameters with a 
direct impact on incremental costs were varied by ±30% (price of trastuzumab, price of predictive 
tests, costs of local and regional recurrence and metastatic disease). Medical resource use was not 
varied separately as it was assumed that any related uncertainty would be covered by the variation of 
unit costs. The discount rate was set to 0% and 6%. 
Additionally, variables subject to statistical uncertainty (sensitivity and specificity of IHC and FISH, 
metastatic, local and regional recurrence rates, utilities) were varied within their 95% confidence 
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intervals (CIs) [48]. The prevalence of a normal (negative) HER-2 expression pattern was varied 
between 75% and 85%.  
Probabilistic sensitivity analysis 
Uncertainty around the base case results was additionally assessed by probabilistic sensitivity 
analysis (PSA), using 10,000 sets of parameter values randomly sampled from beta distributions 
reflecting the ranges of variation used in deterministic sensitivity analysis[49]. Parameters covered 
included HER-2 prevalence, utilities, transition probabilities, and test sensitivity and specificity. Unit 
costs were not subject to uncertainty and therefore not included in the PSA[44]. 
Model implementation  
The Markov model was implemented in TreeAge Pro® 2009 (TreeAge Software Inc, Williamstown, MA, 
USA). 
Results 
Base case analysis 
Effect 
Differences in effectiveness between the strategies involving trastuzumab treatment arose from 
imperfect sensitivity and specificity of the testing strategies (Table 1). Some HER-2-positive patients 
had false negative test results and hence did not receive trastuzumab, which lead to a loss of QALYs. 
Therefore, the no testing strategy (where all patients received trastuzumab) accrued most QALYs 
(12.751 QALYs per patient). The testing strategies accrued between 12.741 and 12.750 QALYs. At 
the lower end, the no-trastuzumab strategy resulted in 12.254 QALYs (Table 4). 
Costs 
Trastuzumab substantially increased costs in both the testing and non-testing strategies, compared to 
no trastuzumab treatment. However, the increase was distinctly lower in the testing strategies. Here, 
trastuzumab costs were strongly reduced as therapy was targeted to those patients who profited most 
(Table 4).  
Per-patient total lifetime costs in the predictive testing strategies ranged from €38’153 (FISH 
confirmation of IHC 2+) to €41’830 (parallel IHC and FISH). FISH confirmation of IHC 2+ saved €62 in 
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comparison to FISH alone. If FISH alone was used, per-patient savings compared to IHC alone and 
parallel IHC and FISH would be €1’736 and €3’615, respectively.  
Incremental cost-effectiveness 
The reference (no-trastuzumab) strategy was least costly and least effective (€32’258 and 12.254 
QALYs per patient) (Table 4). FISH alone testing was associated with a per-patient cost of €38,215 
and resulted in 12.741 QALYs, corresponding to an ICER of €12’245/QALY when compared with the 
no trastuzumab strategy. This was the most favourable ICER observed. FISH alone testing dominated 
IHC alone and FISH confirmation of IHC 2+. In the latter comparison, FISH alone was in a situation of 
extended dominance[50], e.g.it was slightly more expensive but showed a better incremental cost-
effectiveness ratio than the comparator. Superior characteristics of the FISH test lead to a gain in 
clinical effectiveness and hence, clinical savings that over-compensated or near-compensated much 
higher test costs. The ICER of parallel IHC and FISH was €400’154/QALY compared to FISH alone. 
ICERs for the non testing approach were prohibitively high. Figure 2 summarizes cost-effectiveness 
results. 
Current Swiss data show an annual average of 5’091 incident breast cancer cases between 2001-
2005[51]. On this basis, FISH confirmation of IHC 2+ versus FISH alone would lead to cost savings of 
€315’642, and lose 245 QALYs, per year. FISH alone compared to IHC alone would save €8’837’976, 
and gain 177 QALYs, per year. FISH alone compared to parallel IHC and FISH would lead to savings 
of €18’403’965 and a loss of 46 QALYs. 
Sensitivity analysis 
In deterministic sensitivity analysis, varying the price of trastuzumab and the discount rate had 
substantial influence on the results. Variation of other unit costs (apart from trastuzumab), cancer 
recurrence rates, test sensitivity or specificity, utilities or the HER-2 overexpression pattern did not 
influence the ranking of strategies. The ICERs for the non-dominated strategies were essentially 
sustained in all situations analyzed (Figure 3, Table 5). The rank order of the testing strategies was 
also robust (Table 5). However, if the specificity of FISH alone was set a low value of 0.82 (while 
specificity was left unchanged for the other strategies), FISH confirmation of IHC2+ would become the 
preferred strategy due to its much higher specificity value. None of the other analyses performed 
affected the preferability of FISH alone (Figure 3). 
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At a willingness to pay per QALY gained of €13’333, the FISH testing approach became dominant until 
at €380’000, parallel FISH and IHC became the preferred strategy (Figure 4a). Further PSA results are 
shown in Figure 4b. 
Discussion 
We modelled the cost-effectiveness of different predictive HER-2 testing strategies, prior to 
trastuzumab treatment of adjuvant breast cancer patients, from a Swiss health system perspective. 
FISH alone testing with subsequent trastuzumab treatment of HER-2-positive patients was identified 
as the most cost-effective approach, with an ICER of €12’245 per QALY gained compared to no 
trastuzumab use. It dominated other testing strategies or these showed unfavourable cost-
effectiveness ratios. Sensitivity analysis showed these results to be robust over a wide range of 
assumptions. As a limitation, we did not take into account a possible influence of false positive and 
false negative test results on the event risks reported in HERA and in the other trials used for deriving 
transition probabilities in this modelling study. This would have required complex correction 
procedures and tentative assessments indicated a minor impact. 
In routine practice, many local laboratories only use IHC. Central laboratories often use FISH to 
confirm IHC 2+, as was the case in the HERA study[12]. Both of these strategies were dominated by 
the FISH alone strategy in our model. The inferiority (extended domination) of FISH confirmation of 
IHC2+ was due to this strategy's clinical characteristics, although it was cheaper than FISH alone.  
In Switzerland, many central laboratories have started to use primary FISH assays. However, IHC may 
be added in unclear cases. The implications were difficult to assess as no sensitivity or specificity data 
for FISH equivocal samples (HER-2/CEP17 ratio signal between 1.8 and 2.2) were available from the 
literature. A tentative assessment assuming a hypothetical sensitivity of 0.892 (CI 0.766-0.94[30, 31]) 
indicated a quality-adjusted survival of 12.470 QALYs and hence no further gain in clinical 
effectiveness. 
In a recent cost-effectiveness analysis in the metastatic setting, conducted by Elkin et al., trastuzumab 
treatment without predictive testing was dominated by a testing strategy not covered here, namely the 
confirmation of IHC 2+ or 3+ with FISH[26]. Only patients with a positive result in both tests received 
trastuzumab, i.e. considerably fewer than in our combined IHC and FISH strategy. It may indeed make 
sense to use stricter criteria for trastuzumab treatment in the metastatic than in the adjuvant setting. 
However, the strategy of FISH confirmation of IHC 2-3+ was also assessed for non-metastatic 
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patients. In a meta-analysis by Dendukuri et al.[17], focusing on invasive breast cancer patients, and 
in a Swedish cost-effectiveness analysis studying adjuvant breast cancer patients[27], it was again 
identified as the strategy with the best ICER. Of note, the former study only took into account 
diagnostic costs; it disregarded trastuzumab costs[17]. The latter estimated IHC scores from FISH 
results, based on Elkin et al.[26], and thus made an implicit assumption of dependency of IHC and 
FISH. In a separate implementation of the model, we estimated the lifetime costs and effects of the 
strategy defined by Elkin et al. in the adjuvant setting. After reducing sensitivity (0.892, CI 0.766-0.94) 
and increasing specificity (0.975, CI 0.950-0.989)[30, 31], costs summed up to €36’706 in combination 
with 12.697 QALYs gained. Indeed, this would imply a favourable ICER. However, due to a low 
practical relevance in the adjuvant setting, and presumable lack of acceptability in a resource-rich 
setting, we did not incorporate this strategy into the main analysis. 
Recent evidence suggests that HER-2 expression in primary and advanced tumour tissue may be 
discordant by 5-10%[52-57]. HER-2 status may therefore be re-assessed before starting trastuzumab 
treatment in metastatic breast cancer patients experiencing disease progression. However, our model 
focuses on adjuvant therapy and we did not attempt to assess the economic implications of this 
approach, as currently, this is not routine practice.  
A recent review favours FISH over IHC for accuracy, reproducibility and precision reasons[16]. 
According to this source, 15-48% of equivocal IHC 2+ breast cancers show HER-2 gene amplification. 
In addition, 2-8% of IHC 0/1+ breast cancers are FISH amplified. Around 5-22% of IHC 3+ breast 
cancers have no gene amplification (false negativity)[16]. Additionally, a positive FISH status points 
towards a stronger responsiveness to trastuzumab. The use of FISH testing diminishes the number of 
patients eligible for trastuzumab therapy due to both superior sensitivity and specificity compared to 
IHC[16]. These findings favour primary FISH testing and are consistent with our health economic 
result.  
Conclusion 
Clinically useful predictive tests with reasonable sensitivity and specificity to predict drug-response are 
one cornerstone in achieving a cost-effective implementation of new treatment strategies in oncology. 
Currently, many novel predictive assays (e.g. k-ras testing in colorectal cancer, EGFR mutation 
analysis in lung cancer) are being introduced. Results from carefully conducted health economic 
analyses should inform future guidelines on the use of such tests. In the adjuvant breast cancer 
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setting, primary FISH testing with subsequent trastuzumab treatment of HER-2-positive patients is a 
cost-effective and preferable approach. 
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Figure legend 
Figure 1. Markov model starting with the disease free health state 
Figure legend: Diagram of model structure, comprising five health states: disease free, local 
recurrence, regional recurrence, metastasis (distant recurrence) and death.  
 
Figure 2. Cost-effectiveness analysis 
Figure legend: Graphical representation of incremental cost-effectiveness results. IHC alone (2-3+) is 
dominated by FISH alone, i.e. less effective and more expensive. IHC First (FISH only 2+) is in an 
extendedly dominated by FISH alone, i.e. less expensive but also less cost-effective. For the 
remaining strategies, the slope of the dotted line represents incremental cost- effectiveness. 
 
Figure 3.  Plot of the deterministic sensitivity analyses for parameter uncertainty with 
regard to the ICER of FISH testing compared with no trastuzumab  
Figure legend: Larger bars indicate stronger sensitivity of the base case ICER of FISH testing versus 
the reference strategy, to uncertainty around the respective parameters.  
DF, disease free; FISH, fluorescence in situ hybridisation; ICER, incremental cost-effectiveness ratio; 
IHC, immunhistochemistry; LLR, local/regional recurrence; LR, local recurrence; MD, metastatic 
disease; MR, metastatic recurrence; NT, no trastuzumab; P, probability; RR, regional recurrence; 
Sens, sensitivity; Spec, specificity; T, trastuzumab. *In this sensitivity analysis, FISH confirmation of 
IHC 2+ becomes the preferred strategy with an ICER of €13,448 compared to reference strategy.  
 
Figures 4.  Results from the probabilistic sensitivity analysis (PSA) 
Figure 4a.  Acceptability frontier 
Figure legend: The cost-effectiveness acceptability frontier shows the PSA-based probability of testing 
strategies of being cost-effective. For different willingness to pay thresholds, different strategies are 
optimal. For each threshold, only the probability for the optimal strategy is shown. 
 
Figure 4b.  Incremental cost (€) - effectiveness scatter plot of all testing options 
Figure legend: The cost-effectiveness scatter plot uses the cost-effectiveness plane to plot a test cost 
and effectiveness pair for each recalculation of the model (10’000 runs).  
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Table 1. Testing strategies and test characteristics  
 Test strategy Test Cut-off for 
HER-2 
positivity 
Sensitivity 
(±95%CI) 
Specificity 
(±95%CI) 
Ref. 
IHC  2+ and 3+ 0.91 
(0.88-0.94)  
0.75 
(0.72-0.77) 
[30] 1.  All  
All  FISH ≥2.0# 0.98  
(0.87-1.0) 
0.9  
(0.82-0.95) 
[30] 2.  
IHC  2+ and 3+ 
 
3.   
 
All, parallel 
testing* 
FISH* ≥2.0# 
0.9982 
(0.9844-1.0) 
0.675 
(0.5904-0.7515) 
[30, 
31] 
First all IHC 3+ 4.  
Second: If IHC 
2+ 
FISH ≥2.0# 
0.905  
(0.893-0.933) 
0.987  
(0.976-0.992) 
[17] 
5.  No test, all 
trastuzumab 
     
6.  No test, no 
trastuzumab° 
     
*BTP; Belief the positive. 1 positive test is enough for + results. Negative result if both test -  
#ratio HER-2/CEP17 signal 
°Reference strategy 
NB: Sensitivity and specificity of the combined tests remain in sequential or parallel testing order the same[58].  
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Table 2. Annual transition probabilities  
HER-2 status 
Trastuzumab 
 + 
yes 
+ 
no 
- 
yes 
 - 
no 
Ref. 
Disease state Transition to      
Disease-free Disease-free 0.934 0.879 0.975 0.975 
 Local recurrence 0.01 0.022 0.004 0.004 
 Regional recurrence 0.006 0.008 0.004 0.004 
 Metastatic disease° 0.05 0.091 0.017 0.017 
[11, 12, 
59] 
Local 
recurrence 
Disease-free 0.878 0.878 0.878 0.878 
 Local recurrence 0.028 0.028 0.028 0.028 
 Metastatic disease ° 0.094 0.094 0.094 0.094 
[35] 
Regional 
recurrence 
Disease-free 0.895 0.895 0.895 0.895 [34] 
 Metastatic disease ° 0.105 0.105 0.105 0.105  
Metastatic 
disease 
Metastatic disease ° 0.78 0.67 0.788 0.788 
 Death 0.22 0.33 0.212 0.212 
[7, 36] 
°Transition probabilities only shown for first five years. In the subsequent cycles, the model assumed a declined 
recurrence rate of 10% after each cycle.  
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Table 3.  Cost per type of resource use (per first year in € per patient)  
Type of resource Duration / 
amount 
Unit cost (€) Ref. 
Hormonal therapy  1 year 2'233 [44, 47] 
Trastuzumab price (Herceptin®, Roche, Switzerland)  1 vial per 150mg 
1 vial per 440mg 
860 
2'341 
[47] 
Trastuzumab treatment (inkl. Infusion and 4x 
echocardiography) 
1 year 42'588 [44, 47] 
IHC test 1 test 53 [44] 
FISH test1 2 test probes 686 [44] 
Gynaecological examination2 1 142 [44] 
Mammography 1 107 [44] 
Sonography 1 year 100 [44] 
Surgery 1 year 1'2753 
2'7784 
[44] 
Material 1 year 167 [44] 
Anesthesia 1 year 540 [44] 
Radiotherapy 1 year 4'6885 
8'4676 
[44] 
Hospitalization 7.6 days 2'2817 [60] 
1Based on the resource use in Swiss laboratories 
2According to the Swiss Consortium for Gynaecological Oncology and Obstetrics (AGO)[40]: 4 examinations per 
year in the years 1-3, 2 examinations in the years 4-5, one examination in the years 5-10 and biennial 
examinations thereafter 
3Local recurrence in the breast 
4Thoracic local recurrence and regional recurrence 
5For thoracic local recurrence 
6For regional recurrence 
7Average duration of stay of C500 to C509 (ICD10 classification) during 2005 in Switzerland 
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Table 4. Base case cost-effectiveness analysis (CEA) of different testing strategies (reference: no 
trastuzumab) 
Test strategy Lifetime 
cost per 
person  
Lifetime 
efficacy 
C/E Incremental 
costsa 
Incremental 
efficacyb 
ICER 
Unit € QALY €/QALY € QALY €/QALY 
NO trastuzumab* 32'258 12.254 2'632 - - - 
IHC first (FISH only 
for IHC 2+) 
38'153 12.693 3’006 (5’895)d (0.4384)d 
 
Dominatedd 
FISH alone 38'215 12.741 2’999 5’957c 0.4865c 12’245c 
IHC alone 39'951 12.706 3’144 (1’736)e (-0.0348)e Dominatede 
Parallel IHC and 
FISH 
41'830 12.750 3‘281 3‘615f 0.0090f 400‘154f 
NO test  53'860 12.751 4'224 12‘030g 0.0009g 13‘456‘577g 
*Reference strategy 
aRelative to the strategy with the next lower cost 
bRelative to the strategy with the next lower efficacy 
cCompared to the reference strategy (no trastuzumab) 
dExtendedly dominated by FISH alone (Extended dominance: is applied to remove from consideration strategies 
whose cost-effectiveness is inferior in comparison with at least one more expensive strategy) 
eDominated by FISH alone (Simple dominance: a strategy is dominated by another if the former both costs more 
and is less effective) 
fCompared to FISH alone  
gCompared to Parallel IHC and FISH 
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Table 5. One-way sensitivity analysis of incremental costs (€) per QALY gained (ICER) without 
dominated strategies  
Testing strategy FISH alone vs. no 
trastuzumab 
Parallel testing* 
vs. FISH alone 
NO TEST vs. 
parallel testing 
Baseline 12’245 400’154 13’456’577 
Price trastuzumab +30% 15'982 531'788 17'377'558 
Price trastuzumab -30% 8'507 268'544 9'549'342 
Price all predictive tests +30% 12'398 398'547 13'396'396 
Price all predictive tests -30% 12'091 401'785 13'530'503 
Cost of FISH test probe -50% 11’892 400’129 13’655’867 
Cost metastatic basis treatment +30%°# 11'806 399'727 13'463'011 
Cost metastatic basis treatment -30%°# 12'683 400'605 13'463'889 
Cost local recurrence +30%° 12'181 400'102 13'463'386 
Cost local recurrence -30%° 12'308 400'230 13'463'514 
Cost regional recurrence +30%° 12'243 400'164 13'463'448 
Cost regional recurrence -30%° 12'246 400'168 13'463'451 
Discount rate 6% 18'721 636'009 21'215'854 
Discount rate 0% 7'644 230‘451 7‘818‘473 
°without consideration of hormone-therapy 
#price for trastuzumab not included 
*Parallel both tests (BTP): Either IHC (2-3+) or FISH+ test result needed for HER-2+ status 
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Figure 1.  
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Figure 2.  
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Figure 3.  
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Figure 4a.  
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Figure 4b.  
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